AI Article Synopsis

  • Mutations in the IDH1 gene are prevalent in low-grade gliomas and secondary glioblastomas, driving tumor growth through the conversion of α-ketoglutarate to the oncometabolite 2-hydroxyglutarate.
  • Inhibitors like AG-120 and AG-881 show promise in treating these tumors, though measuring their effectiveness can be difficult without visible tumor growth changes.
  • This study identified potential metabolic imaging biomarkers, specifically using H- and C-magnetic resonance spectroscopy, to track treatment responses by monitoring levels of 2-HG and glutamate in glioma cells.

Article Abstract

Mutations in isocitrate dehydrogenase 1 (IDH1mut) are reported in 70-90% of low-grade gliomas and secondary glioblastomas. IDH1mut catalyzes the reduction of α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG), an oncometabolite which drives tumorigenesis. Inhibition of IDH1mut is therefore an emerging therapeutic approach, and inhibitors such as AG-120 and AG-881 have shown promising results in phase 1 and 2 clinical studies. However, detection of response to these therapies prior to changes in tumor growth can be challenging. The goal of this study was to identify non-invasive clinically translatable metabolic imaging biomarkers of IDH1mut inhibition that can serve to assess response. IDH1mut inhibition was confirmed using an enzyme assay and H- and C- magnetic resonance spectroscopy (MRS) were used to investigate the metabolic effects of AG-120 and AG-881 on two genetically engineered IDH1mut-expressing cell lines, NHAIDH1mut and U87IDH1mut. H-MRS indicated a significant decrease in steady-state 2-HG following treatment, as expected. This was accompanied by a significant H-MRS-detectable increase in glutamate. However, other metabolites previously linked to 2-HG were not altered. C-MRS also showed that the steady-state changes in glutamate were associated with a modulation in the flux of glutamine to both glutamate and 2-HG. Finally, hyperpolarized C-MRS was used to show that the flux of α-KG to both glutamate and 2-HG was modulated by treatment. In this study, we identified potential H- and C-MRS-detectable biomarkers of response to IDH1mut inhibition in gliomas. Although further studies are needed to evaluate the utility of these biomarkers , we expect that in addition to a H-MRS-detectable drop in 2-HG, a H-MRS-detectable increase in glutamate, as well as a hyperpolarized C-MRS-detectable change in [1-C] α-KG flux, could serve as metabolic imaging biomarkers of response to treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392019PMC
http://dx.doi.org/10.7150/thno.47317DOI Listing

Publication Analysis

Top Keywords

biomarkers response
12
idh1mut inhibition
12
ag-120 ag-881
8
metabolic imaging
8
imaging biomarkers
8
response idh1mut
8
h-mrs-detectable increase
8
increase glutamate
8
glutamate 2-hg
8
idh1mut
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!